Epigenetics

Epigenetics is the control of gene expression without altering the DNA sequence, including DNA methylation, genomic imprinting, maternal effects, gene silencing, nucleolus dominant, dormant transposon activation, and RNA editing. In contrast to classical genetics, which focuses on the effects of gene sequences on biological functions, epigenetics focuses on the mechanisms by which these "epigenetic phenomena" are established and maintained.

Cat. No.	Product name
BP13738	BRD9539
BP13738	BRD9539 is an inhibitor of euchromatin histone methyltransferase 2 (EHMT2), also known as G9a, with an IC50 value of 6.3 μM
BP13737	BRD7-IN-1
BP13737	BRD7-IN-1, a modified derivative of BI7273 (BRD7/9 inhibitor), binds to a VHL ligand via a linker to form a PROTAC VZ185 (VZ185 against BRD7/9 with DC50s of 4.5 and 1.8 nM, respectively).
BP13736	BRD73954
BP13736	BRD73954, an effective and specific HDAC inhibitor, which is with IC50 of 36 nM and 120 nM for HDAC6 and HDAC8, respectively.
BP13735	BRD-6929
BP13735	BRD-6929 is a selective, brain-penetrant HDAC1 and HDAC2 inhibitor (IC50: 1 and 8 nM). BRD-6929 (Cpd-60) shows high-affinity to HDAC1 and HDAC2 (Kis: 0.2 and 1.5 nM). BRD-6929 potentiates the efficacy of gnidimacrin (a PKC Agonist) against latent HIV-1. BRD-6929 can be used for mood-related behavioral model research.
BP13734	BRD6688
BP13734	BRD6688 is a selective HDAC2 inhibitor that acts by enhancing the learning and memory processes
BP13733	BRD4770
BP13733	BRD4770 is a histone methyltransferase G9a inhibitor and induces cell senescence.
BP13732	BRD4 Inhibitor-10
BP13732	BRD4 Inhibitor-10 is an inhibitor of BRD4-BD1 (IC50: 8 nM).
BP13731	BRD4 degrader AT1
BP13731	BRD4 degrader AT1 is a highly selective Brd4 degrader based on PROTAC technology, with a Kd of 44 nM for Brd4BD2 in cells.
BP13730	BRD0639
BP13730	BRD0639 is a potent PRMT5 inhibitor. BRD0639 engages the target in cells, disrupts PRMT5-RIOK1 complexes, and reduces substrate methylation. BRD0639 is a first-in-class PBM-competitive inhibitor that can support studies of PBM-dependent PRMT5 activities and the development of novel PRMT5 inhibitors that selectively target these functions.
BP13729	BRD 4354
BP13729	BRD 4354 is an inhibitor of HDAC5 and HDAC9. For HDAC5 and HDAC9, the IC50s values are 0.85 and 1.88 μM, respectively.
BP13728	BRD 4354 ditrifluoroacetate
BP13728	BRD 4354 (ditrifluoroacetate) is a moderately potent inhibitor of HDAC5 and HDAC9 (IC50s: 0.85 and 1.88 μM).
BP13727	Bobcat339
BP13727	Bobcat339 is a novel cytosine-based TET enzyme inhibitor (IC50s: 33/73 uM for TET1/2), but not DNMT3a, does not inhibit the DNA methyltransferase DNMT3a.
BP13726	BMS-P5
BP13726	BMS-P5 is a specific and orally active Peptidylarginine Deiminase 4 (PAD4) inhibitor.
BP13725	BMS-P5 free base
BP13725	BMS-P5 free base is a specific and orally active peptidylarginine deiminase 4 (PAD4) inhibitor. BMS-P5 Blocks Formation of Neutrophil Extracellular Traps and Delays Progression of Multiple Myeloma. Administration of BMS-P5 to multiple myeloma-bearing mice delays appearance of symptoms and disease progression Targeting PAD4 may be beneficial for treatment of multiple myeloma.
BP13724	BMS-986158
BP13724	BMS-986158 is a potent BET inhibitor with IC50s of 6.6 and 5 nM in NCI-H211 small cell lung cancer (SCLC) cells and MDA-MB231 triple negative breast cancer (TNBC) cells, respectively.
BP13723	BJE6-106
BP13723	BJE6-106 (B106) is a potent, selective PKCδ inhibitor (IC50: 0.05 μM) and targets selectivity over classical PKCα (IC50: 50 μM). BJE6-106 induces caspase-dependent apoptosis with tumor-specific effect.
BP13722	Bisindolylmaleimide V
BP13722	Bisindolylmaleimide V, a bisindolylmaleimide derivative, is an inactive of a kinase inhibitor.
BP13721	Bisindolylmaleimide IV
BP13721	Bisindolylmaleimide IV is a protein kinase C (PKC) cell permeable inhibitor( IC50 : 0.10 - 0.55 μM)
BP13720	Bisdemethoxycurcumin
BP13720	Bisdemethoxycurcumin (BDMC) is a natural demethoxy derivative of curcumin. It is a potent activator of macrophage phagocytosis, interacting with 1α, 25-dihydroxy vitamin D3 to stimulate amyloid-β clearance by macrophages (optimal stimulation at 100 nM BDMC). More stable than curcumin in physiological media, BDMC suppresses proliferation of cancer cells. It down-regulates the transcriptional coactivator p300, suppressing the Wnt/β-catenin pathway, and inhibits LPS induction of iNOS expression.
BP13719	Birabresib
BP13719	Birabresib is a synthetic, small molecule inhibitor of the BET (Bromodomain and Extra-Terminal) family of bromodomain-containing proteins 2, 3 and 4 with potential antineoplastic activity.